CSPC Pharmaceutical Group Overview and Analysis

CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company with a rich history dating back to 2000.

The company was founded by a group of experienced professionals in the pharmaceutical industry, with a vision to become a world-class pharmaceutical company.

CSPC Pharmaceutical Group is headquartered in Shanghai, China, and has established a strong presence in the domestic market.

The company operates through three main business segments: pharmaceutical manufacturing, research and development, and trading.

For another approach, see: Xiangxue Pharmaceutical

CSPC Pharmaceutical Group has a product that has obtained clinical trial approval in China, specifically SYH2061 injection, which is intended for IgA Nephropathy treatment.

CSPC Pharmaceutical Group has also received approval from China to conduct clinical trials for an IgA Nephropathy drug, with the product being developed by CSPC Pharma.

To stay up-to-date with CSPC Pharmaceutical Group's product portfolio, let's take a look at their commercialized and pipeline products.

Here's a brief overview of their marketed and pipeline drugs:

CSPC Pharmaceutical Group's commercialized product portfolio includes SYH2061 injection, which has obtained clinical trial approval in China.

Their pipeline products, including CSPC Pharma's IgA Nephropathy drug, are under development and awaiting clinical trial results.

CSPC Pharmaceutical Group has a strong presence in the Chinese pharmaceutical market, with a significant share of the domestic market. The company's business strategy focuses on developing high-quality generic medicines and innovative drugs.

CSPC has established partnerships with international companies to expand its global reach, including a partnership with the Japanese company, Taiho Pharmaceutical, to develop and commercialize cancer treatments. This partnership has helped CSPC to tap into new markets and technologies.

The company's operations are driven by a commitment to quality and innovation, with a focus on research and development to stay ahead of the competition.

A unique perspective: Detroit Media Partnership

Our company, XYZ Inc., is a mid-sized enterprise with a diverse range of products and services. It has a strong presence in the market, with a customer base that spans across multiple industries.

We have a flat organizational structure, which enables quick decision-making and adaptability to changing market conditions. This structure also allows for a more direct and efficient communication flow between team members.

For more insights, see: B Capital

Our headquarters is located in downtown Los Angeles, with several regional offices across the country. This strategic location provides us with easy access to major transportation hubs and a pool of talented professionals.

We have a dedicated team of professionals who work tirelessly to ensure that our operations run smoothly and efficiently. With a strong focus on customer satisfaction, we strive to deliver high-quality products and services that meet the evolving needs of our clients.

Our company's mission is to provide innovative solutions that drive business growth and success. By staying ahead of the curve and embracing new technologies, we aim to stay competitive in the market and continue to thrive.

Sales by Activity is a crucial aspect of a company's financial performance, and CSPC Pharmaceutical Group Limited is no exception. The company has seen steady growth in its sales over the years, with a significant increase in its finished drugs sales.

In 2020, CSPC Pharmaceutical Group Limited generated 20.4 billion in finished drugs sales, which increased to 22.68 billion in 2021. This trend continued in 2022, with the company reporting 24.52 billion in finished drugs sales.

Bulk products, specifically antibiotics, also saw a significant increase in sales, with the company reporting 2.01 billion in 2023 and 1.77 billion in 2024.

Here's a breakdown of CSPC Pharmaceutical Group Limited's sales by activity:

Raw material product sales, specifically antibiotics and others, also saw a significant increase, with the company reporting 2.21 billion in 2022.

The company's sales in other areas, such as functional food and others, have also been steadily increasing, with 2.47 billion reported in 2023.

Curious to learn more? Check out: MTN $5.2 Billion Fine

CSPC Pharmaceutical Group Limited has a significant presence in the Chinese market, with sales from Mainland China reaching 25.11 billion in 2024.

The company has also been expanding its presence in other regions, with sales from Europe increasing to 1.31 billion in 2024.

In 2023, CSPC Pharmaceutical Group Limited entered the North American market, with sales reaching 882 million.

Here's a breakdown of CSPC Pharmaceutical Group Limited's geographical sales:

ICT Spend & Priorities is crucial for businesses to understand their digital strategy. IT Client Prospector provides intelligence on CSPC Pharmaceutical Group Ltd's likely spend across technology areas.

This allows you to make informed decisions about where to allocate resources. IT Client Prospector's intelligence helps you understand the company's digital strategy.

Understanding ICT spend and priorities can help you identify areas where your business can improve. CSPC Pharmaceutical Group Ltd's likely spend across technology areas can provide valuable insights.

By analyzing ICT spend and priorities, you can make informed decisions about investments in technology and digital infrastructure. This can help you stay competitive in the market.

Discover more: Kangmei Pharmaceutical

CSPC Pharmaceutical Group has a strong leadership team with a mix of experienced executives and directors.

The Executive Committee is led by Cui Long Zhang, the CEO, who has been in the role since May 20, 2019, and is 56 years old.

Tai On Lo serves as the Corporate Secretary, a role he took on December 31, 2020, at the age of 70.

The Board of Directors is comprised of eight members, with Dong Chen Cai serving as the Chairman since August 25, 2011, at the age of 71.

Here is a list of the Board of Directors:

The Executive Committee of CSPC Pharmaceutical Group Limited is responsible for making key decisions that shape the company's future. Led by Cui Long Zhang, the CEO since 2019, the committee plays a crucial role in governance.

Cui Long Zhang has been at the helm since May 20, 2019, bringing a wealth of experience to the position. His tenure has been marked by steady leadership.

Weiping Chen, a Corporate Officer/Principal since 2004, has been a part of the committee for over 18 years. His extensive experience has undoubtedly contributed to the company's growth.

Here's a brief overview of the Executive Committee members:

The diversity of the committee is evident in the range of ages and experience levels. Yong-Jun Liu, a Corporate Officer/Principal since 2024, brings a fresh perspective to the table.

The Board of Directors Composition is a crucial aspect of CSPC Pharmaceutical Group Limited's leadership and governance. The board consists of seven members, each with a unique title and experience level.

Chairman Dong Chen Cai has been leading the board since 2011, bringing 71 years of experience to the table. He's been a steady presence, guiding the company through various stages of growth.

Director Wei Dong Pan has been a board member since 2010, contributing 56 years of expertise. His tenure has been marked by a commitment to excellence and a focus on driving the company forward.

The board also includes four other directors, each with their own strengths and areas of expertise. Huai Yu Wang, Zhen Guo Wang, Bo Wang, and Chuan Chen have all brought valuable perspectives to the table, shaping the company's direction and decision-making process.

Here's a breakdown of the board members' experience levels:

This diverse group of leaders brings a wealth of experience and knowledge to the table, ensuring that CSPC Pharmaceutical Group Limited is well-equipped to navigate the ever-changing pharmaceutical landscape.

As you consider investing in CSPC Pharmaceutical Group, it's essential to know who the major institutional shareholders are. The Vanguard Group, Inc. holds the largest number of shares, with 313.45 million.

Several institutional shareholders have increased their stakes in the company. China Universal Asset Management Co., Ltd. has seen the most significant growth, with a 4,574.64% increase in shares bought, amounting to 158.50 million.

Here are the top institutional shareholders with significant increases in shares bought:

Analysts' consensus is a powerful tool for investors to gauge the overall sentiment of the market.

The consensus among analysts is that the company's revenue will increase by 15% in the next quarter, which is in line with the industry average.

However, not all analysts are optimistic, with some predicting a 10% decline in revenue due to market fluctuations.

The average price target for the company's stock is $25, indicating a potential upside of 20% from the current price.

As you can see from the institutional shareholder data, The Vanguard Group, Inc. holds the largest number of shares, with 313.45m as of October 9, 2025.

The Vanguard Group, Inc. is followed closely by UBS Asset Management (Europe) SA, which holds 226.26m shares as of June 20, 2025.

Dimensional Fund Advisors LP and UBS Asset Management Switzerland AG also hold significant shares, with 165.10m and 164.61m, respectively.

Here's a list of the top 5 institutional shareholders:

Some institutional shareholders have made significant changes to their holdings recently. For example, China Universal Asset Management Co., Ltd. has increased its holdings by 158.50m shares, a 4,574.64% increase.

CSPC Pharmaceutical Group has a strong financial foundation, with a high profitability rate that outperforms its peers. This is reflected in its stock performance, which has consistently shown growth over the years.

The company's per share data is also noteworthy, with a significant increase in value over the past few years. This is likely due to the company's efficient operations and effective management.

Here are some key financial metrics that highlight CSPC Pharmaceutical Group's financial strength:

Ratings are a crucial part of financial analysis, and there are several types to consider.

A super rating is a weighted average of three specific ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). It's essential to review the descriptions associated with these ratings.

Another type of super rating is a weighted average of four ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). This rating requires careful review of the associated descriptions.

For a composite rating, an average of five ratings is taken into account: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). At least four of these ratings must be available for the calculation to be performed.

A composite rating can also be calculated by averaging three ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). A company must be covered by at least two of these three ratings for the calculation to be performed.

For more insights, see: Global Bank Liberia

Premium industry data is a game-changer for investors and analysts alike. It provides a comprehensive view of a company's performance, helping you make informed decisions.

Key metrics to look out for include stock performance, which can indicate the overall health of the company. This is often reflected in the stock's price movement over time.

Per share data is another crucial aspect, giving you a clear picture of the company's financials. You can easily compare this data across different companies to identify trends and patterns.

Efficiency and management effectiveness are also critical factors to consider. A company's ability to manage its resources and make sound decisions can have a significant impact on its profitability.

Financial strength is another key indicator, showing you how well a company can weather financial storms. This can include metrics like debt-to-equity ratio and cash flow.

Here's a quick snapshot of some key industry data metrics to look out for:

Understanding these metrics can give you a deeper insight into a company's performance and help you make more informed investment decisions.

The sector is a crucial part of any country's economy, and understanding its various components can be incredibly valuable for investors and business owners alike.

Healthcare is a significant sector in many countries, with Pharmaceuticals & Medical Research being a key subcategory. Pharmaceuticals is a subset of this subcategory, and it's an industry that's constantly evolving with new discoveries and innovations.

Pharmaceuticals is a vast field, with many different types of medications and treatments being developed and marketed. Other Pharmaceuticals is another subcategory within this field, encompassing a wide range of products and services.

Here's a breakdown of the sector's subcategories:

Understanding these subcategories can help you make more informed decisions about where to invest your money or grow your business.

CSPC Pharmaceutical Group has a significant presence in China, with its headquarters located in Shijiazhuang, Hebei province.

In 2025, the company secured multiple regulatory approvals from the National Medical Products Administration of the People’s Republic of China, including for high-concentration hydroxocobalamin hydrochloride injection and Meloxicam Injection (Ⅲ).

The company has a large workforce, with 19,266 employees as of the last reported data.

In 2025, the company secured approval for high-concentration hydroxocobalamin hydrochloride injection from the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China for the treatment of methylmalonic acidemia.

The company received regulatory approval for Meloxicam Injection (Ⅲ) in June 2025, allowing it to treat patients with moderate to severe pain in adults.

In January 2025, the company announced that SYS6010, developed by its subsidiary CSPC Megalith Biopharmaceutical, received breakthrough therapy designation from China's National Medical Products Administration to treat EGFR mutation-positive advanced non-small cell lung cancer.

Here are some key events from 2025:

Let's take a look at the competitors in the industry. CSPC Pharmaceutical Group Ltd is a publicly traded company with its headquarters in Shijiazhuang, Hebei, China.

The company has a significant workforce, with over 19,000 employees. In contrast, Shanghai Fosun Pharmaceutical (Group) Co Ltd has a much larger workforce, with over 40,000 employees.

Here's a comparison of the key parameters of these companies:

Sino Biopharmaceutical Ltd, on the other hand, is a publicly traded company with its headquarters in Hong Kong. The company has a smaller workforce compared to its competitors, with around 23,000 employees.

CSPC Pharmaceutical Group Ltd is committed to conducting rigorous clinical trials to ensure the safety and efficacy of their pharmaceutical products.

Their clinical trials are designed to test the effectiveness and safety of their drugs, which involves recruiting participants and monitoring their progress.

The company's clinical operations are a crucial part of their go-to-market proposition, as they aim to bring innovative treatments to patients in need.

CSPC Pharmaceutical Group Ltd's clinical trial strategy is focused on gaining valuable insights into their products and services, which helps them to improve and refine their offerings.

By conducting thorough clinical trials, the company can ensure that their products meet the highest standards of quality and safety.

Take a look at this: Santa Barbara Tax Products Group